Ligand Pharmaceuticals LGND Gain (Loss) on Short-term Investments
Gain (Loss) on Short-term Investments at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:GainLossOnShortTermInvestments.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's gain (loss) on short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's gain (loss) on short-term investments?
- Ligand Pharmaceuticals (LGND) reported gain (loss) on short-term investments of $3.87M in Q1 2026.
- How has Ligand Pharmaceuticals's gain (loss) on short-term investments changed year-over-year?
- Ligand Pharmaceuticals's gain (loss) on short-term investments increased by 131.3% year-over-year, from -$12.37M to $3.87M.
- What does gain (loss) on short-term investments mean?
- This represents the realized or unrealized gains or losses recognized on the company's short-term investment portfolio during the reporting period. It reflects the performance of liquid assets held outside of core operations. Monitoring this helps distinguish between income generated from business activities versus income derived from treasury management.